EU/3/19/2212

Table of contents

About

On 17 October 2019, orphan designation EU/3/19/2212 was granted by the European Commission to Minoryx Therapeutics S.L., Spain, for leriglitazone (also known as MIN-102) for the treatment of Friedreich’s ataxia.

Key facts

Active substance
leriglitazone
Disease / condition
Treatment of Friedreich’s ataxia
Date of first decision
17/10/2019
Outcome
Positive
EU designation number
EU/3/19/2212

Sponsor's contact details

Minoryx Therapeutics S.L.
Calle Ernest Lluch 32 Tcm 2
08302 Mataro Barcelona
Spain
Tel: +34935441466
E-mail: xortega@minoryx.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating